Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders April 14, 2026 9:30 AM EDTCompany ParticipantsMeg Alexander ...
Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 ...
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase ...
View Ovid Therapeutics Inc. OVID stock quote prices, financial information, real-time forecasts, and company news from CNN.
Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programs Development to focus on serious ...
According to deal terms announced Monday, New York-based Ovid will pay AstraZeneca $12.5 million up front, breaking down to $5 million in cash $7.5 million in shares of publicly traded Ovid. Milestone ...
Barbara Weiden Boyd is a big fan of Ovid, the Latin poet who died just about two thousand years ago. Apart from being a great humorist, she said, Ovid should be applauded for his brilliant re-working ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results